Systemic antifungal therapy generally requires continuous dosing over an extended duration of treatment, which can often lead to decreased patient compliance. The unique pharmacokinetic profile of itraconazole permits its administration by use of an intermittent, pulse dosing regimen. Mycologic cure rates of ≥75% were achieved in 6 of 12 studies of itraconazole pulse therapy in the treatment of toenail onychomycosis, and 60-74% in 4 of the remaining 6. In treating dermatomycoses, intermittent pulse regimens of itraconazole offer patients a high degree of efficacy and enhanced safety, as well as shorter treatment duration and lower costs of therapy. Worldwide over the past 15 years, itraconazole has been administered to more than 40 million patients, with no reports of any serious toxicity; any associated side effects have been only minor and transient.